A new approach to treating renal anaemia.
Accepted version
Peer-reviewed
Repository URI
Repository DOI
Change log
Authors
Abstract
Erythropoiesis-stimulating agents (ESAs) are widely used to treat anaemia in patients with kidney disease. A potential alternative approach is to increase erythropoietin production using small-molecule inhibitors of prolyl hydroxylase domain (PHD) enzymes. Recent phase III trials of the PHD inhibitor roxadustat demonstrate similar efficacy and safety to ESAs.
Description
Keywords
Journal Title
Nat Rev Nephrol
Conference Name
Journal ISSN
1759-5061
1759-507X
1759-507X
Volume Title
15
Publisher
Springer Nature
Publisher DOI
Rights and licensing
Except where otherwised noted, this item's license is described as All rights reserved
Sponsorship
Wellcome Trust (096956/Z/11/Z)
Wellcome Trust Senior Investigator Award
Rosetrees Trust